WO2007091253A3 - Pharmaceutical compositions comprising clopidogrel and vitamins which reduce homocysteine levels - Google Patents

Pharmaceutical compositions comprising clopidogrel and vitamins which reduce homocysteine levels Download PDF

Info

Publication number
WO2007091253A3
WO2007091253A3 PCT/IL2007/000155 IL2007000155W WO2007091253A3 WO 2007091253 A3 WO2007091253 A3 WO 2007091253A3 IL 2007000155 W IL2007000155 W IL 2007000155W WO 2007091253 A3 WO2007091253 A3 WO 2007091253A3
Authority
WO
WIPO (PCT)
Prior art keywords
clopidogrel
vitamins
pharmaceutical compositions
homocysteine levels
vitamin
Prior art date
Application number
PCT/IL2007/000155
Other languages
French (fr)
Other versions
WO2007091253A2 (en
Inventor
Shlomo Halfon
Neil Somers
Rina Yamin
Sigal First
Original Assignee
C T S Ltd
Shlomo Halfon
Neil Somers
Rina Yamin
Sigal First
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by C T S Ltd, Shlomo Halfon, Neil Somers, Rina Yamin, Sigal First filed Critical C T S Ltd
Publication of WO2007091253A2 publication Critical patent/WO2007091253A2/en
Publication of WO2007091253A3 publication Critical patent/WO2007091253A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Pharmaceutical compositions comprising a combination of clopidogrel and one or more vitamins for reducing blood homocysteine levels, such as folic acid, a pyridoxine salt, preferably pyridoxine hydrochloride (vitamin B6), and cyanocobalamin (vitamin B12), are useful in the treatment or prevention of pathologies induced by platelet aggregation, preferably cardiovascular, peripheral vascular or homocysteine related disorders or diseases.
PCT/IL2007/000155 2006-02-06 2007-02-06 Pharmaceutical compositions comprising clopidogrel and vitamins which reduce homocysteine levels WO2007091253A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76520006P 2006-02-06 2006-02-06
US60/765,200 2006-02-06

Publications (2)

Publication Number Publication Date
WO2007091253A2 WO2007091253A2 (en) 2007-08-16
WO2007091253A3 true WO2007091253A3 (en) 2009-04-09

Family

ID=38345539

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2007/000155 WO2007091253A2 (en) 2006-02-06 2007-02-06 Pharmaceutical compositions comprising clopidogrel and vitamins which reduce homocysteine levels

Country Status (1)

Country Link
WO (1) WO2007091253A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104001176B (en) * 2014-06-11 2016-06-22 深圳奥萨医药有限公司 The pharmaceutical composition of platelet ADP receptor antagonist and vitamin B group
CN113456821A (en) * 2021-07-01 2021-10-01 苏州大学 Combined pharmaceutical composition for preventing cardiovascular diseases complicated by hypertension and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429210B1 (en) * 1998-06-15 2002-08-06 Sanofi-Synthelabo Polymorphic clopidogrel hydrogenesulphate form
US20030077297A1 (en) * 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6429210B1 (en) * 1998-06-15 2002-08-06 Sanofi-Synthelabo Polymorphic clopidogrel hydrogenesulphate form
US20030077297A1 (en) * 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6669955B2 (en) * 2001-08-28 2003-12-30 Longwood Pharmaceutical Research, Inc. Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin

Also Published As

Publication number Publication date
WO2007091253A2 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
IL259851A (en) Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
IL189578A (en) Pyridine derivatives, pharmaceutical compositions comprising them and uses thereof in the preparation of medicaments for the treatment of cns disorders
WO2006044101A3 (en) Method and composition for supplementation of nutritional deficiencies in renal patients
IL206296A (en) Aminopyrazole derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments for prevention or treatment of diseases
WO2006120682A3 (en) Compositions and methods for treating hyperproliferative epidermal diseases
MY148723A (en) Use of pinolenic acid for the treatment of obesity
WO2006116221A3 (en) Therapeutic combinations for the treatment or prevention of psychotic disorders
WO2007027761A3 (en) Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease
IL207038A (en) Diazaspiro[5.5]undecane derivatives, pharmaceutical compositions comprising the same and uses thereof in the preparation of medicaments for treating or reducing the risk of an inflammatory disease or condition
IL197128A (en) Pyridone derivatives, pharmaceutical compositions comprising them and their use in the manufacture of medicaments for influencing eating behavior
MX2013000319A (en) Treatment of cognitive disorders.
WO2007041368A3 (en) Dpp iv inhibitor for use in the treatment of autoimmune diseases and graft rejection
WO2009134086A3 (en) Pharmaceutical formulation for treatment of cardiovascular disease
CY1112547T1 (en) Means Containing Folic Acid, Vitamin B6 And Vitamin B12, And Their Use
EP2012807A4 (en) Pharmaceutical composition of enterosorbent and prebiotics, dosage forms, and the method for prevention and treatment of gastrointestinal disorders
WO2007093880A3 (en) Novel pyrone-indole derivatives and process for their preparation
WO2008029237A3 (en) Combination therapies for rheumatoid arthritis
WO2008094825A3 (en) Compositions and methods for maintaining, strengthening, improving or promoting eye health
WO2012125981A3 (en) Raf kinase inhibitors
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2009010810A3 (en) Cardiovascular combinations comprising ace and hmg-co-a inhibitors
WO2006128048A3 (en) Methods and compositions for reducing blood homocysteine levels
WO2009118726A3 (en) Oral combination of vitamins
WO2008010008A3 (en) Cardiovascular combinations using rennin-angiotensin inhibitors
WO2007091253A3 (en) Pharmaceutical compositions comprising clopidogrel and vitamins which reduce homocysteine levels

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07706098

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07706098

Country of ref document: EP

Kind code of ref document: A2